MODULATION OF MELATONIN SECRETION BY ACETYL-L-CARNITINE IN ADULT AND OLD RATS

被引:7
|
作者
ESPOSTI, D
MARIANI, M
DEMARTINI, G
LUCINI, V
FRASCHINI, F
MANCIA, M
机构
[1] UNIV MILAN,INST HUMAN ANAT,DEPT PHARMACOL,I-20133 MILAN,ITALY
[2] GERIATR INST REDAELLI,VIMODRONE,ITALY
关键词
MELATONIN SECRETION; PINEAL HYPERSENSITIVITY; ACETYL-L-CARNITINE; YOUNG AND OLD RATS;
D O I
10.1111/j.1600-079X.1994.tb00124.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Modification of melatonin synthesis and release by acetyl-l-carnitine (ALC) was studied in adult (2 month old) and old (24-month-old) male Sprague Dawley rats. When ALC was injected at 1500 into adult rats at doses of 10, 30, or 90 mg/kg, there was a remarkable increase in their pineal and serum melatonin 1 hr later. However, using the same experimental protocol acute ALC administration in old rats did not modify pineal and serum melatonin levels. ALC administered in the same dose range induced a significant increase in pineal and serum melatonin in adult rats treated at 0100 h following exposure of 30 min to bright, white light to suppress endogenous melatonin. In the same conditions, in old rats, only the higher dose (90 mg/kg) caused any noteworthy increase in melatonin pineal content while lower doses were uneffective both on serum and pineal melatonin levels. It is known that ALC affects fatty acid transport in the cells, modulates CoA, modifies neuronal transmission and reduces lipofuscin accumulation which is related to lipid peroxidation. The action of ALC on melatonin synthesis could be the result of a modulation of the neuronal transmission related to circadian pineal endocrine activity. Moreover, since both ALC and melatonin exert remarkable scavenger activity, it is possible to suppose that ALC effects in reversing certain aging processing may be due to its ability to promote melatonin production.
引用
收藏
页码:132 / 136
页数:5
相关论文
共 50 条
  • [41] Acetyl-L-carnitine role in fibromyalgia syndrome
    Giorgi, Valeria
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (06) : 8 - 8
  • [42] Use of Acetyl-L-Carnitine in Gerontological Practice
    Ponomareva E.V.
    Neuroscience and Behavioral Physiology, 2019, 49 (4) : 451 - 455
  • [43] Mechanisms of ischemic neuroprotection by acetyl-L-carnitine
    Zanelli, SA
    Solenski, NJ
    Rosenthal, RE
    Fiskum, G
    NEUROPROTECTIVE AGENTS, 2005, 1053 : 153 - 161
  • [44] REYE SYNDROME MODEL IN RATS - PROTECTION AGAINST LIVER ABNORMALITIES BY L-CARNITINE AND ACETYL-L-CARNITINE
    VISENTIN, M
    BELLASIO, R
    TACCONI, MT
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1995, 275 (02): : 1069 - 1075
  • [45] NEURAL DYSFUNCTION AND METABOLIC IMBALANCES IN DIABETIC RATS PREVENTION BY ACETYL-L-CARNITINE
    IDO, Y
    MCHOWAT, J
    CHANG, KC
    ARRIGONIMARTELLI, E
    ORFALIAN, Z
    KILO, C
    CORR, PB
    WILLIAMSON, JR
    DIABETES, 1994, 43 (12) : 1469 - 1477
  • [46] Acetyl-L-carnitine treatment stimulates oxygen consumption and biosynthetic function in perfused liver of young and old rats
    M.P. Mollica
    S. Iossa
    S. Soboll
    G. Liverini
    Cellular and Molecular Life Sciences CMLS, 2001, 58 : 477 - 484
  • [47] Effects of acetyl-L-carnitine on regional cerebral glucose metabolism in awake rats
    Ori, C
    Freo, U
    Pizzolato, G
    Dam, M
    BRAIN RESEARCH, 2002, 951 (02) : 330 - 335
  • [48] Anti-Inflammatory and Antioxidant Effects of Acetyl-L-Carnitine on Atherosclerotic Rats
    Wang, Shixun
    Xu, Jingtao
    Zheng, Jiahui
    Zhang, Xincai
    Shao, Jingbo
    Zhao, Luyan
    Hao, Junqiang
    MEDICAL SCIENCE MONITOR, 2020, 26
  • [49] Acetyl-l-Carnitine Ameliorates Caerulein-induced Acute Pancreatitis in Rats
    Arafa, Hossam M. M.
    Hemeida, Ramadan A. M.
    Hassan, Mohamed I. A.
    Abdel-Wahab, Mohammed H.
    Badary, Osama A.
    Hamada, Farid M. A.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 (01) : 30 - 36
  • [50] Effect of acetyl-L-carnitine on ethanol consumption and alcohol abstinence syndrome in rats
    Mangano, NG
    Clementi, G
    Costantino, G
    Calvani, M
    Matera, M
    DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 2000, 26 (01) : 7 - 12